Dulaglutide is a long-acting GLP-1 receptor agonist (once-weekly subcutaneous injection). Reduces HbA1c, weight, and cardiovascular risk.
Also known as: Trulicity
Very long-acting (weekly) GLP-1 receptor agonist. Molecule chemically linked to IgG4 Fc.
Binds to the GLP-1 receptor, stimulating glucose-dependent insulin secretion and suppressing glucagon secretion. IgG4 Fc binding prolongs half-life.
Oral bioavailability: <1% (must be injected). SC absorption: ~65%. Tmax: 24-72 hours.
Metabolised by protease to amino acids and fatty acid. Does not interfere with CYP.
~4-5 days (allows weekly dosing). Elimination: ~60% urine (metabolites), ~30% faeces.
No documented drug–drug interactions for this medicine.
No documented food or drink interactions.
No documented disease interactions.
No documented pregnancy or breastfeeding information.
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
